Walgreens has entered a multi-year partnership with Freenome to advance the clinical trials of the latter’s blood-based tests for early cancer detection.

Walgreens will work with technology provider Curebase to initially enrol patients across diverse populations for Freenome’s Sanderson Study.

The study is designed to assess blood-based early detection tests for several cancers. It will enrol roughly 8,000 participants via its clinical study partner network, which includes Walgreens.

Walgreens chief clinical trials officer Ramita Tandon said: “Through our nationwide presence and trusted pharmacists, we can reach and engage previously underserved patient populations for clinical trials.”

Walgreens will use Curebase’s platform to deliver targeted outreach to eligible participants and caregivers of all backgrounds through email, text or in-person consultation at the pharmacy.

Eligible patients will be recruited in the study upon completion of the pre-screen process.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Later, healthcare providers from Walgreens will conduct a single blood draw at one of the company’s trial sites.  They will also follow up with patients through telehealth one year after their participation.

Furthermore, both entities will build population health software and risk-prediction models to address existing care gaps and identify people who can benefit from standard-of-care cancer detection testing.

Real-world data from Walgreens through the collaboration will help develop new products and services in Freenome’s multi-cancer detection research, including the blood-based screening test for colorectal cancer. 

Freenome chief medical officer Lance Baldo said: “With community reach, study conduct capabilities, national presence and real-world data generation resources, Walgreens is a natural partner to help deliver on that goal.”